PMID- 8851724
OWN - NLM
STAT- MEDLINE
DCOM- 19961205
LR  - 20190826
IS  - 0001-2815 (Print)
IS  - 0001-2815 (Linking)
VI  - 47
IP  - 2
DP  - 1996 Feb
TI  - The human leukocyte antigen TAP2 gene defines the centromeric limit of melanoma 
      susceptibility on chromosome 6p.
PG  - 117-21
AB  - A single human leukocyte antigen (HLA) class II allele, DQB1*0301, is strongly 
      associated with melanoma, and the HLA-DR locus provides the telomeric boundary 
      for melanoma susceptibility in the HLA class II region of chromosome 6. However, 
      the centromeric boundary is unknown. This study was designed to determine whether 
      the adjacent upstream transporter associated with antigen processing (TAP) locus, 
      TAP2, constitutes the centromeric boundary of disease susceptibility in melanoma. 
      Molecular oligotyping of TAP2 genes was performed for 36 Caucasian patients with 
      melanoma and for 32 Caucasian control individuals by both amplification 
      refractory mutation system (ARMS) polymerase chain reaction (PCR) and 
      PCR-sequence-specific oligonucleotide (SSO) typing. TAP2 allele frequencies in 
      the melanoma patients were compared to those in non-melanoma Caucasian control 
      populations, and to HLA-DQ allele frequencies determined by molecular 
      oligotyping. While HLA-DQB1*0301 was more common in this group of 36 melanoma 
      patients compared to a group of 200 controls (56 percent vs. 27 percent, 
      Bonferoni-corrected chi-square p < = 0.01), no significant differences were 
      observed in TAP2 allele frequencies between melanoma patients and controls. The 
      TAP2 locus represents the centromeric boundary of disease susceptibility for 
      melanoma in the class II region of chromosome 6p. These results support an 
      etiologic role for HLA-DQB1*0301 in melanoma susceptibility.
FAU - Lee, J E
AU  - Lee JE
AD  - Department of Surgical Oncology, University of Texas, M.D. Anderson Cancer 
      Center, Houston, USA.
FAU - Loflin, P T
AU  - Loflin PT
FAU - Laud, P R
AU  - Laud PR
FAU - Lu, M
AU  - Lu M
FAU - Reveille, J D
AU  - Reveille JD
FAU - Lawlor, D A
AU  - Lawlor DA
LA  - eng
GR  - CA16672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B, Member 3)
RN  - 0 (ATP-Binding Cassette Transporters)
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 145892-13-3 (TAP2 protein, human)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B, Member 3
MH  - ATP-Binding Cassette Transporters/*genetics
MH  - Centromere
MH  - *Chromosomes, Human, Pair 6
MH  - Disease Susceptibility
MH  - HLA-DQ Antigens/*genetics
MH  - HLA-DQ beta-Chains
MH  - Humans
MH  - Leukocytes/immunology
MH  - Melanoma/*genetics/immunology
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
AID - 10.1111/j.1399-0039.1996.tb02523.x [doi]
PST - ppublish
SO  - Tissue Antigens. 1996 Feb;47(2):117-21. doi: 10.1111/j.1399-0039.1996.tb02523.x.